---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-23-008275"
form_type: "8-K"
ticker: "BGLC"
cik: "0001737523"
company_name: "BioNexus Gene Lab Corp"
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:17:40.440111+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioNexus Gene Lab receives Nasdaq bid-price deficiency notice

## Summary
- Closing bid price below $1.00 for 33 consecutive business days (Sept 20 - Nov 3, 2023).
- 180-day compliance period ends May 6, 2024; cure requires $1.00 close for 10 straight days.
- Company may be eligible for an additional 180-day cure period if it meets other listing standards.
- Failure to cure could result in delisting from Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001477932-23-008275
- form_type: 8-K
- ticker: BGLC
- cik: 0001737523
- company_name: BioNexus Gene Lab Corp
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737523/000147793223008275/0001477932-23-008275-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737523/000147793223008275/bglc_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-23-008275
- JSON: https://secwatch.observer/filing/0001477932-23-008275.json
- Plain text: https://secwatch.observer/filing/0001477932-23-008275.txt

## Key facts
- Listing & Compliance Notices
  BioNexus Gene Lab Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: November 6, 2023, BioNexus Gene Lab Corp. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) regarding the Company’s failure to comply with Nasdaq Continued Listing Rule (“Rule”) 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. A failure to comply with Rule 5550(a)(2) exists when listed securities fail to maintain a closing bid price of at least $1.00 per share for 30 consecutive business days. Based on the closing bid price for the last 33 consecutive business days (including, in pa
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737523/000147793223008275/0001477932-23-008275-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.